| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 81.10 mm | 81.10 mm | 81.10 mm | 81.10 mm | 81.10 mm | 81.10 mm |
| Cash burn (monthly) | 256.67 k | (no burn) | 20.67 mm | 18.51 mm | 10.76 mm | 11.08 mm |
| Cash used (since last report) | 1.03 mm | n/a | 83.19 mm | 74.48 mm | 43.29 mm | 44.59 mm |
| Cash remaining | 80.07 mm | n/a | -2.09 mm | 6.62 mm | 37.80 mm | 36.51 mm |
| Runway (months of cash) | 311.9 | n/a | -0.1 | 0.4 | 3.5 | 3.3 |
| 13F holders | Current |
|---|---|
| Total holders | 154 |
| Opened positions | 25 |
| Closed positions | 17 |
| Increased positions | 59 |
| Reduced positions | 31 |
| 13F shares | Current |
|---|---|
| Total value | 656.06 bn |
| Total shares | 67.78 mm |
| Total puts | 373.40 k |
| Total calls | 107.90 k |
| Total put/call ratio | 3.5 |
| Largest owners | Shares | Value |
|---|---|---|
| Deep Track Capital | 5.97 mm | $66.95 bn |
| BlackRock | 5.22 mm | $58.50 bn |
| T. Rowe Price | 4.83 mm | $54.20 mm |
| FMR | 3.90 mm | $43.71 bn |
| Vanguard | 3.53 mm | $39.53 bn |
| Redmile | 3.20 mm | $35.84 bn |
| Paradigm Biocapital Advisors | 3.10 mm | $34.80 bn |
| Blue Owl Capital | 3.00 mm | $33.68 bn |
| First Light Asset Management | 2.58 mm | $28.87 bn |
| Novartis Institutes for BioMedical Research | 2.15 mm | $40.98 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 23 Jan 25 | Bernard Coulie | Common Stock | Grant | Acquire A | No | No | 0 | 162,500 | 0.00 | 593,017 |
| 23 Jan 25 | Bernard Coulie | Stock Option Common Stock | Grant | Acquire A | No | No | 11.14 | 325,000 | 3.62 mm | 325,000 |
| 23 Jan 25 | Keith Lamont Cummings | Common Stock | Grant | Acquire A | No | No | 0 | 56,650 | 0.00 | 319,258 |
| 23 Jan 25 | Keith Lamont Cummings | Stock Option Common Stock | Grant | Acquire A | No | No | 11.14 | 113,300 | 1.26 mm | 113,300 |
| 23 Jan 25 | Lefebvre Eric | Common Stock | Grant | Acquire A | No | No | 0 | 45,650 | 0.00 | 240,224 |
| 23 Jan 25 | Lefebvre Eric | Stock Option Common Stock | Grant | Acquire A | No | No | 11.14 | 91,300 | 1.02 mm | 91,300 |
| 23 Jan 25 | Hull Hans | Common Stock | Grant | Acquire A | No | No | 0 | 40,150 | 0.00 | 251,708 |
| 23 Jan 25 | Hull Hans | Stock Option Common Stock | Grant | Acquire A | No | No | 11.14 | 80,300 | 894.54 k | 80,300 |
| 23 Jan 25 | Mike Ouimette | Common Stock | Grant | Acquire A | No | No | 0 | 35,000 | 0.00 | 105,544 |
| 23 Jan 25 | Mike Ouimette | Stock Option Common Stock | Grant | Acquire A | No | No | 11.14 | 70,000 | 779.80 k | 70,000 |
